Ahmedabad-based pharma player Lincoln Pharmaceuticals Limited posted a standalone net profit of ₹9.23 crore for the fourth quarter ended March 2020, as against ₹7.17 crore in the same quarter last year, showing a 29-per cent growth on year-on-year basis.

Company’s standalone revenues for the quarter stood at ₹81 crore, as against ₹77 crore in the same quarter last year.

For the financial year 2019-20, its net profit stood at ₹50 crore as against ₹47 crore in the previous year, indicating a growth of about 6 per cent.

Mahendra Patel, MD, Lincoln Pharmaceuticals, said, “Company’s performance during the quarter and full year has been quite remarkable amidst the challenging economic and business scenario prevailing across the globe. Exports sales (FOB) for the year increased 7 per cent to ₹211 crore. Company has seen good traction in the export business, which is expected to get further boost once EU operations begins.”

On consolidated basis, its net profit for the quarter stood at ₹9 crore, as against ₹8.5 crore in the corresponding quarter last year.

Consolidated revenues for the quarter stood at ₹83 crore as against ₹78 crore in the same quarter last year.

For the fiscal 2020, its consolidated net profit stood at ₹51 crore as against ₹49 crore in the previous year. Consolidated revenues for the year stood at ₹398 crore as against ₹372 crore last year.

On Thursday,. Lincoln Pharmaceuticals shares gained 2.5 per cent to ₹176.50 on the BSE.

Related Topics